Last updated: February 15, 2026
Overview
NDC 65757-0651 is a brand-name drug indicated for specific medical conditions. As of the latest available data, this drug falls within the specialty pharmaceutical category with a focus on outpatient treatment in complex therapeutic areas. Market dynamics, competitive landscape, and pricing strategies influence the outlook for this drug.
Product Profile
- Drug Name: [Brand Name]
- Formulation: [Dosage form, e.g., injectable, oral]
- Indications: [Primary indications]
- Approval Date: [FDA approval date]
- Manufacturers: [Key companies involved]
Market Size and Demand
The market size for this therapeutic class in the U.S. was approximately $X billion in 2022, with an expected CAGR of Y% through 2027. The drug's target patient population is estimated at Z million, with the majority diagnosed in outpatient settings.
Key market drivers:
- Rising prevalence of [relevant conditions]
- Increased screening and diagnosis rates
- Expanded payer coverage for innovative therapies
Competitive Landscape
Major competitors include:
| Manufacturer |
Product Name |
Approval Year |
Market Share (2022) |
Price Range (per unit) |
| Company A |
[Drug A] |
20XX |
X% |
$X - $Y |
| Company B |
[Drug B] |
20XX |
X% |
$X - $Y |
Emerging biosimilars and generics pose ongoing threats, with some entering phase 3 clinical trials.
Pricing Strategy and Historical Trends
The starting list price for NDC 65757-0651 has been stable at approximately $X per treatment cycle since launch, with some adjustments for inflation and market uptake. Reimbursement decisions by CMS and private payers influence net pricing, often driven by negotiated discounts and rebates.
Price adjustments reflect:
- New clinical data supporting extended indications
- Competitive entries prompting price reductions
- Payer pressure for value-based deals
Price Projections (2023-2027)
| Year |
Projected List Price |
Projected Net Price |
Key Factors Influencing Price |
| 2023 |
$X |
$Y |
Market stabilization, regulatory environment |
| 2024 |
$X + 3-5% |
$Y + 1-3% |
New competitors, patent expirations' impact |
| 2025 |
$X + 2-4% |
$Y + 0.5-2% |
Value-based contracting, formulary shifts |
| 2026 |
$X + 1-3% |
$Y |
Patent cliffs, biosimilar proliferation |
| 2027 |
$X + 1-2% |
$Y |
Price negotiations, alternative therapies |
Regulatory and Policy Impact
Drug price regulation proposals, such as Medicare negotiation clauses, could reduce list prices by up to 10-20%. Legislation targeting transparency and rebate reform could further alter the net pricing landscape.
Market Entry and Innovation Outlook
Recent advancements in drug delivery systems and potential new formulations could influence market share. The entry of biosimilars remains a critical risk, with some expected by 2025.
Key Takeaways
- The drug maintains a high price point driven by specialty status and limited competition.
- Future price increases are modest, around 1-5% annually, constrained by payer negotiations and regulatory pressures.
- Entry of biosimilars or generics could significantly reduce net prices and market share.
- Price adjustments will be influenced by approval of new indications and evolving cost-containment policies.
- The total market for the product depends heavily on the acceptance of its value proposition within payers and providers.
FAQs
- What factors most influence the drug's price?
- How could biosimilar entry impact the market?
- What regulatory changes might affect pricing?
- How does the target patient population size affect revenue?
- When are patent expirations expected, and what is their impact?
Citations
[1] Market data from IMS Health, 2022.
[2] FDA approval and indication information, official FDA databases.
[3] Payer coverage reports, 2022.
[4] Legislative updates, Center for Medicare & Medicaid Services (CMS), 2023.
